Zydus receives approval from COFEPRIS of Mexico to market ‘Bhava’ to treat various cancers

Bayer announces positive topline results for Nubeqa from Phase III trial in men with mHSPC

Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT

Industry hails Union Budget 2024-25

The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable

Health Minister Nadda chairs a training program for street food vendors

The innovative ‘Street Safe’ Rapid Testing Kit should be provided to all vendors attending the Food Safety and Certification (FoSTaC) trainings to ensure that safe food is used by the street food vendors across the country

Rusan Pharma’s API plant in Ankleshwar receives USFDA GMP approval

Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well

Budget 2024-25: Industry expects push for reforms, R&D and fiscal incentives

Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23

Singhi Advisors facilitates acquisition of 85% stake of GMP Technical Solutions by Japanese Shinryo Corporation

This transaction is the third acquisition by three different Japanese players in this segment

Elucid appoints Kelly Huang as CEO

Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software

Merck starts commercial production of first GMP-compliant manufacturing line for cell culture media in China

€ 6.6 million investment at Nantong site expands production capabilities for cell culture media

ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024

Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain